Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY – Research Report) and Merus (MRUS – Research Report) with bullish sentiments.
Alnylam Pharma (ALNY)
In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Alnylam Pharma, with a price target of $384.00. The company’s shares closed last Thursday at $266.59.
According to TipRanks.com, Ijem is a 3-star analyst with an average return of 4.1% and a 43.3% success rate. Ijem covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Rocket Pharmaceuticals, and Rhythm Pharmaceuticals.
Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $316.85, implying a 15.0% upside from current levels. In a report issued on October 16, Scotiabank also initiated coverage with a Buy rating on the stock with a $305.00 price target.
See the top stocks recommended by analysts >>
Merus (MRUS)
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Merus, with a price target of $67.00. The company’s shares closed last Thursday at $49.93.
According to TipRanks.com, Newman is a 3-star analyst with an average return of 1.9% and a 38.2% success rate. Newman covers the Healthcare sector, focusing on stocks such as Cartesian Therapeutics, Allogene Therapeutics, and Atara Biotherapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Merus with a $86.14 average price target, a 69.5% upside from current levels. In a report issued on October 24, UBS also initiated coverage with a Buy rating on the stock with a $72.00 price target.
Read More on ALNY: